INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in TransMedics Group, Inc of Class Action Lawsuit and Upcoming Deadlines - TMDX

Core Viewpoint - A class action lawsuit has been filed against TransMedics Group, Inc, alleging securities fraud and other unlawful business practices [1][2]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP for participation in the class action, with a deadline to apply as Lead Plaintiff by April 15, 2025 [3]. - The lawsuit follows accusations from U.S. Representative Paul Gosar regarding misconduct, including misappropriation of corporate resources [3]. Group 2: Stock Price Impact - Following the publication of Representative Gosar's letter, TransMedics' stock price dropped by $3.85 per share, or 4.43%, closing at $83.14 on February 23, 2024 [4]. - On January 10, 2025, after Scorpion Capital's report detailing alleged fraudulent practices, the stock price fell by $3.74 per share, or 5.16%, closing at $68.81 [6]. Group 3: Allegations Against TransMedics - Scorpion Capital's report claims TransMedics engaged in fraudulent billing, off-label misuse of devices, and relied on kickbacks for sales [5]. - The report also highlights ongoing investigations by the U.S. Department of Justice and other agencies into Medicare fraud related to organ acquisition costs, along with customer dissatisfaction leading to the discontinuation of device use by prominent transplant centers [5].